Merck buys Mirus Bio to boost viral vector bioprocessing capacity

Merck KGaA has concluded the acquisition of Mirus Bio for €500m ($600m), enhancing its viral vector bioprocessing capabilities.

Related Posts

Adcendo and Multitude ink ADC deal potentially worth $1bn

Aug 21, 2024

UK to provide up to £39m for AMR research

May 22, 2023

STAT+: Another major pharma company departs BIO

Jan 4, 2024